EYEGATE PHARMACEUTICALS INC 4
4 · EYEGATE PHARMACEUTICALS INC · Filed Mar 1, 2017
Insider Transaction Report
Form 4
GOLDBERG MORTON
Director
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2017-02-27−1,083→ 1,917 totalExercise: $1.70Exp: 2026-01-25→ Common Stock (1,083 underlying) - Exercise/Conversion
Common Stock
2017-02-27$1.70/sh+1,083$1,841→ 18,360 total
Footnotes (1)
- [F1]The reporting person was granted an option to purchase these shares pursuant to the Issuer's 2014 Equity Incentive Plan. The option became exercisable as to 33% of the shares underlying the option on January 25, 2017, with 2.78% of the shares underlying the option vesting monthly thereafter.